Introduction
Testicular germ cell tumors (GCTs) represent one of oncology's greatest treatment successes, with cure rates exceeding 95% overall and greater than 80% even in metastatic disease. The backbone of this success is platinum-based combination chemotherapy, principally BEP (bleomycin, etoposide, cisplatin) and EP (etoposide, cisplatin). However, as the survivor population grows—predominantly comprising adolescent and young adult (AYA) males with decades of life remaining—meticulous attention to dosing precision, toxicity management, fertility preservation, and long-term survivorship has become inseparable from curative intent. This review synthesizes current guideline-based evidence through May 2026, providing practical, actionable guidance for clinicians managing testicular cancer across special populations.
Standard Dosing Frameworks and Cycle Scheduling
The standard BEP regimen is administered in 21-day cycles: bleomycin 30,000 International Units (IU) intravenously on days 1, 8, and 15; etoposide 100 mg/m² intravenously on days 1–5; and cisplatin 20 mg/m² intravenously on days 1–5 116. Risk stratification per the International Germ Cell Cancer Collaborative Group (IGCCCG) determines the number of cycles: good-prognosis disease typically receives 3 cycles (total bleomycin 270,000 IU), while intermediate- and poor-prognosis disease receives 4 cycles (total bleomycin up to 360,000 IU) 115. The EP regimen omits bleomycin and is administered for 4 cycles at the same etoposide and cisplatin doses 2. VIP (etoposide, ifosfamide, cisplatin) represents an alternative for intermediate/poor-risk patients when bleomycin is contraindicated 115.
A critical principle across all guidelines is that dose delays and reductions are strongly discouraged, as compromised dose intensity may meaningfully reduce cure rates 2. Pegfilgrastim 6 mg subcutaneously on day 6 is recommended as primary G-CSF (granulocyte-colony stimulating factor) prophylaxis to maintain planned delivery, though the febrile neutropenia risk without G-CSF prophylaxis is approximately 10–20% 1. Mild leukopenia alone should not prompt cycle delays; etoposide is the primary myelosuppressive agent, and transient white blood cell (WBC) decrements during bleomycin administration days (8 and 15) do not routinely warrant complete blood count (CBC) monitoring on those days or deferral of weekly bleomycin doses 17. When dose modification is unavoidable, consultation with a high-volume tertiary center is essential 2.
Antiemetic prophylaxis for cisplatin-based chemotherapy generally includes an NK-1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone, with regimen scheduling varying by institutional protocol and guideline recommendations, combined with dexamethasone 8–12 mg continuing through day 8—is standard given the high emetogenic potential of these regimens 1. Prehydration with magnesium sulfate (10 mmol in 1,000 mL normal saline over 60 minutes) prior to cisplatin, followed by verification of adequate urine output, is mandatory for nephroprotection 1.
The GETUG-13 trial demonstrated a clinically meaningful benefit from personalizing therapy in poor-prognosis NSGCT based on early tumor marker decline. Patients with unfavorable marker decline after one cycle of BEP who were randomized to a dose-dense regimen (paclitaxel-BEP-oxaliplatin followed by cisplatin-ifosfamide-bleomycin) achieved a 5-year progression-free survival of 58.9% versus 46.7% with standard BEP (HR 0.65, P = 0.036), with minimal long-term toxicity 4.
Adolescent and Young Adult (AYA) Patients
AYA patients (ages 15–39) constitute the predominant demographic affected by testicular cancer and present unique clinical and psychosocial challenges. Intensive BEP and EP regimens demand robust supportive care—antiemetics, G-CSF, hydration, electrolyte management—to maximize tolerability and adherence in this population 2. Psychosocial concerns, including anxiety, body image disturbance, and fear of recurrence, affect a substantial proportion; anxiety rates up to 21% have been reported among survivors, underscoring the need for proactive mental health screening 17.
AYA survivors face the longest anticipated post-treatment lifespan, making long-term toxicity surveillance particularly consequential. Structured transition from active treatment to survivorship clinics should explicitly address cardiovascular risk, nephrotoxicity, neuropathy, ototoxicity, secondary malignancy, and reproductive health 2. Transition-of-care planning from pediatric to adult oncology settings requires explicit communication of treatment summaries, late-effect risk profiles, and surveillance protocols. Guideline discordance across survivorship frameworks (Children's Oncology Group Long-Term Follow-Up Guidelines, NCCN AYA Oncology Guidelines) can complicate consistent care delivery; clinicians should select a guideline and apply it systematically while individualizing for patient-specific risk factors 10. Chronic fatigue—reported in up to 44% of survivors treated with high-dose chemotherapy at 28-year follow-up—is a major survivorship burden and is best addressed through structured exercise programs 17.
Fertility Preservation and Reproductive Safety
Gonadotoxicity is an inherent risk of BEP, EP, and all cisplatin-containing regimens, with cumulative dose-dependent impairment of spermatogenesis potentially leading to oligospermia, azoospermia, and possibly irreversible infertility 9. Bleomycin and etoposide contribute additional gonadotoxic potential 9.
Per ASCO 2024 guidelines, sperm cryopreservation (sperm banking) before initiating any cancer-directed therapy is the standard of care for all pubertal and postpubertal males 14. Empirically, a minimum of three ejaculates of sufficient quality should be obtained, though any cryopreserved sample—even of suboptimal quality—offers meaningful fertility preservation potential via intracytoplasmic sperm injection (ICSI) 1418. Banking should occur before treatment; however, it must not delay treatment urgency. For males unable to produce a semen sample, testicular sperm extraction (TESE) with cryopreservation should be offered 1418. Hormonal gonadoprotection (e.g., GnRH agonists) is not recommended in males due to lack of evidence 14.
Contraception counseling is essential: males should use effective contraception during treatment and for at least 11 months after the last cisplatin dose 9. Post-treatment, 71–82% of men attempting conception achieve fatherhood without cryopreserved sperm, though up to 16% of couples require assisted reproductive technology, reinforcing pretreatment banking as a proactive safeguard 18. Baseline and periodic testosterone and luteinizing hormone (LH) monitoring are indicated, as hypogonadism—affecting 5–10% after orchiectomy alone and higher proportions with chemotherapy—may warrant testosterone replacement therapy when symptomatic 17.
Baseline Renal Impairment and Nephrotoxicity Management
Cisplatin nephrotoxicity is dose-dependent and cumulative, with renal impairment characteristically emerging during the second week after administration 5. Patients with baseline creatinine clearance (CrCl) <60 mL/min warrant heightened caution. Guidelines recommend directly measured glomerular filtration rate (mGFR) rather than estimated GFR (eGFR) for cisplatin dosing decisions in patients with suspected renal dysfunction, particularly those with extreme body composition, amputees, or paraplegia 1.
The cornerstone of nephroprotection is aggressive prehydration: 1–2 liters of intravenous fluid over 8–12 hours before cisplatin, with cisplatin diluted in saline-mannitol solution over 6–8 hours, followed by maintained hydration and urine output monitoring for 24 hours post-infusion 5. A repeat cisplatin course should not proceed until serum creatinine is <1.5 mg/dL and/or BUN is <25 mg/dL 5. Electrolyte wasting—hypomagnesemia, hypokalemia, hypocalcemia—is common, requires ongoing monitoring and supplementation, and may persist long-term 15.
When CrCl falls to 40–60 mL/min, EP is preferred over BEP, as eliminating bleomycin reduces the risk of compounded organ toxicity; bleomycin clearance itself is impaired in renal dysfunction, elevating pulmonary toxicity risk 17. For patients with CrCl <40 mL/min, specialist nephrology consultation, potential alternative regimens (carboplatin-based, noting its distinct toxicity profile), and individualized risk-benefit assessment are warranted 1116. Etoposide and bleomycin do not carry primary nephrotoxic mechanisms comparable to cisplatin, though bleomycin's clearance reduction in renal impairment has indirect pulmonary consequences.
Late Effects and Long-Term Survivorship Risks
Cardiovascular disease is a leading cause of non-cancer mortality in testicular cancer survivors. The hazard ratio for acute coronary syndrome (ACS) after cisplatin-based chemotherapy (CBCT) ranges from 1.4 to 3.0, with a median absolute ACS risk of approximately 6% at 19 years 17. Standard cardiovascular risk calculators (Framingham, ASCVD) significantly underestimate true risk because they do not account for cisplatin dose or cisplatin-induced endothelial dysfunction 17. Clinicians must counsel survivors explicitly about this elevated risk and implement aggressive preventive strategies: smoking cessation, blood pressure control, dyslipidemia management, weight management, and regular physical activity 717.
Secondary malignant neoplasms (SMNs) represent the leading cause of death among long-term testicular cancer survivors, with 25-year cumulative incidence of 13–20% for seminoma and 10% for NSGCT survivors 17. Elevated SMN risks have been documented in the thyroid, lung, stomach, pancreas, colon, bladder, and kidney, largely attributable to platinum retention in healthy tissues and/or radiotherapy exposure 17. The combination of CBCT and radiotherapy confers particularly high SMN risk; treatment de-escalation where oncologically appropriate is a priority.
Chemotherapy-induced peripheral neuropathy (CIPN) persists in 30–40% of survivors for several years; 19% report neuropathic pain at a median of 11 years post-treatment 17. Cisplatin-based chemotherapy regimens, including both BEP and EP, are associated with chemotherapy-induced peripheral neuropathy, with cumulative cisplatin exposure being a major determinant of risk. Duloxetine provides moderate clinical benefit for painful CIPN; structured exercise programs have also demonstrated benefit 17.
Bleomycin pulmonary toxicity has an incidence of 5–40%, is cumulative and dose-dependent, and must not exceed 400,000 IU total (with risk escalating substantially beyond 300,000 IU) 1. Risk factors include age >40–50 years, smoking history, renal impairment, and pre-existing pulmonary disease 617. Clinicians should perform baseline pulmonary function testing including DLCO (diffusing capacity of the lungs for carbon monoxide) and immediately evaluate any new nonproductive cough, dyspnea, or basilar rales 117. Post-treatment DLCO typically declines but rebounds during follow-up; long-term pulmonary impairment is limited in most patients who do not undergo pulmonary surgery or develop pulmonary embolism 6.
Cisplatin ototoxicity affects 23–74% of survivors; risk factors include higher cumulative dose, younger age at treatment, and concurrent ototoxic drug use 17. Baseline audiometry and post-treatment surveillance are recommended. Raynaud phenomenon affects approximately 35% of survivors at long-term follow-up and is more prevalent after BEP than EP (24% vs. 12%), implicating bleomycin as a contributing vascular agent 17.
Clinical Decision-Making: BEP vs. EP and Special-Population Considerations
BEP remains the preferred regimen for most good-prognosis metastatic NSGCT when bleomycin is not contraindicated. Retrospective data suggest that BEP × 3 may achieve superior disease control compared to EP × 4, with significantly lower rates of active cancer in post-chemotherapy retroperitoneal lymph node dissection (RPLND) specimens (7.8% vs. 31.9%) 11. EP × 4 is the preferred alternative when bleomycin is contraindicated due to age >50 years, pre-existing pulmonary disease, compromised DLCO, significant renal impairment (which elevates bleomycin systemic exposure), or prior bleomycin exposure approaching cumulative dose limits 131517. VIP × 4 is considered for intermediate/poor-risk disease when bleomycin toxicity is a clinical concern 115. For stage I seminoma, a single cycle of adjuvant carboplatin (AUC 7) represents an alternative to radiotherapy, with a 9-year follow-up series showing no increase in overall or cardiovascular mortality compared to the general population 16.
Summary Table: Regimen-Specific Dosing, Toxicity, and Special-Population Considerations
| Regimen | Typical Dosing | Key Toxicities | Contraindications / Cautions | Special Population Considerations | Monitoring and Counseling |
|---|---|---|---|---|---|
| BEP × 3–4 | Bleomycin 30,000 IU IV days 1, 8, 15; Etoposide 100 mg/m² IV days 1–5; Cisplatin 20 mg/m² IV days 1–5; q21 days | Bleomycin pulmonary fibrosis (5–40%); CIPN (30–40%); ototoxicity (23–74%); nephrotoxicity; Raynaud phenomenon (35%); myelosuppression; hypogonadism; cardiovascular disease | Age >50; renal impairment (CrCl <60); extensive pulmonary metastases; significant pulmonary comorbidity, renal dysfunction affecting bleomycin clearance, or prior clinically significant bleomycin toxicity; prior bleomycin close to cumulative limit | AYA: mandatory sperm banking; psychosocial and transition-of-care support. Renal impairment: avoid if CrCl <60; use mGFR for dosing decisions. Pulmonary disease: baseline PFT/DLCO; discontinue if dyspnea/cough develops | Baseline and serial renal function, electrolytes (Mg²⁺, K⁺), CBC; baseline audiometry; pulmonary function testing; cardiovascular risk assessment at 5–10 years; annual audiometric and renal surveillance; fertility counseling before cycle 1 |
| EP × 4 | Etoposide 100 mg/m² IV days 1–5; Cisplatin 20 mg/m² IV days 1–5; q21 days | Higher CIPN and neutropenia burden vs. BEP; nephrotoxicity; ototoxicity; hypogonadism; cardiovascular disease; lower pulmonary risk | Renal impairment (CrCl <60, use with caution); severe baseline cytopenias | AYA: same fertility counseling as BEP; preferred if pulmonary disease present. Renal impairment: preferred over BEP when bleomycin contraindicated with CrCl 40–60. Age >50: preferred over BEP | Baseline renal function and audiometry; serial electrolytes; CBC; cardiovascular risk assessment at 5–10 years; neuropathy screening; fertility counseling before cycle 1 |
| VIP × 4 (Etoposide, Ifosfamide, Cisplatin) | Cisplatin 20 mg/m² IV days 1–5; Etoposide 100 mg/m² IV days 1–5; Ifosfamide 1.2 g/m² IV days 1–5; q21 days | Myelosuppression; nephrotoxicity; hemorrhagic cystitis; ifosfamide encephalopathy; CIPN; ototoxicity; hypogonadism | CrCl <40; active urinary tract infection; significant CNS comorbidity | Ifosfamide adds gonadotoxicity; mesna uroprotection mandatory. Avoid in severe renal impairment. Monitor CNS symptoms (confusion, hallucinations) | CBC; urinalysis; renal function; electrolytes; CNS symptom screening; baseline and post-treatment audiometry; mesna dosing = ifosfamide dose; fertility counseling |
| Carboplatin AUC 7 × 1 (Stage I seminoma adjuvant) | Carboplatin AUC 7 IV × 1 cycle (Calvert formula) | Myelosuppression; lower nephrotoxicity than cisplatin; lower gonadotoxicity | Platinum allergy; severe renal impairment (use with caution) | Lower gonadotoxicity than BEP/EP; fertility preservation still recommended. Long-term cardiovascular and SMN data still maturing at 9-year follow-up | CBC; renal function; baseline audiometry; long-term cardiovascular surveillance; semen analysis if fertility concerns |
CIPN = chemotherapy-induced peripheral neuropathy; DLCO = diffusing capacity of the lungs for carbon monoxide; mGFR = measured glomerular filtration rate; NSGCT = nonseminomatous germ cell tumor; PFT = pulmonary function test; RPLND = retroperitoneal lymph node dissection; SMN = secondary malignant neoplasm.
Conclusion
BEP and EP remain highly curative regimens for testicular GCTs, but their safe and effective use demands individualized clinical judgment across the full arc of care—from pretreatment assessment and fertility preservation to active treatment toxicity management and structured long-term survivorship follow-up. Dose intensity must be preserved whenever feasible; supportive care with antiemetics, G-CSF, and aggressive hydration is the clinical infrastructure that enables this goal 12. Regimen selection should be tailored to age, renal function, pulmonary status, cumulative bleomycin exposure, and fertility priorities. For all reproductive-age males, sperm banking before the first chemotherapy dose is non-negotiable standard of care 1418. Survivorship planning must address cardiovascular disease, secondary malignancies, neuropathy, hearing loss, pulmonary function, and psychosocial health as lifelong clinical responsibilities—not afterthoughts 17. Cancer diagnosis may provide an opportunity to initiate lifestyle modification and survivorship surveillance strategies that could improve long-term quality of life for this predominantly young and curable patient population 7.